News headlines about Pfizer (NYSE:PFE) have trended somewhat positive on Saturday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pfizer earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.6540887057633 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern’s scoring:
- Quant Score Analytics Limit Pfizer (PFE) Upgrade to Hold (investorplace.com)
- Noticeable Technical Figures – Pfizer Inc. (PFE) – Wall Street Morning (wallstreetmorning.com)
- Healthcare ETFs Head to Head: XLV vs. VHT (finance.yahoo.com)
- Pfizer, Inc. to Post Q4 2017 Earnings of $0.57 Per Share, SunTrust Banks Forecasts (PFE) (americanbankingnews.com)
- Reckitt Benckiser to form two business units for better focus (finance.yahoo.com)
Pfizer (NYSE PFE) opened at 36.42 on Friday. The company has a market capitalization of $216.60 billion, a P/E ratio of 26.64 and a beta of 1.00. Pfizer has a 52 week low of $29.83 and a 52 week high of $36.60. The firm has a 50-day moving average of $35.56 and a 200-day moving average of $33.83.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the business earned $0.64 earnings per share. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. Analysts anticipate that Pfizer will post $2.56 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.51%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio is presently 94.12%.
A number of analysts have recently weighed in on the stock. BMO Capital Markets restated a “buy” rating and issued a $39.00 target price (up from $37.00) on shares of Pfizer in a report on Thursday. Jefferies Group LLC set a $38.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, October 16th. Deutsche Bank AG set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Barclays PLC set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $38.26.
COPYRIGHT VIOLATION NOTICE: “Pfizer (PFE) Receiving Somewhat Positive Press Coverage, Accern Reports” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/10/21/pfizer-pfe-receiving-somewhat-positive-press-coverage-accern-reports.html.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares in the company, valued at $5,074,379. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the transaction, the chief executive officer now owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 464,521 shares of company stock valued at $15,813,961. Company insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.